Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study.
Lars Erik KristensenMauro KeisermanKim PappLeslie McCaslandDouglas WhiteWenjing LuAhmed M SolimanAnn EldredLisa BarcombFrank BehrensPublished in: Rheumatology (Oxford, England) (2022)
ClinicalTrials.gov (http://clinicaltrials.gov): KEEPsAKE1 (NCT03675308).